Droxidopa
- Generic Name
- Droxidopa
- Brand Names
- Northera
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO5
- CAS Number
- 23651-95-8
- Unique Ingredient Identifier
- J7A92W69L7
- Background
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopa...
- Indication
For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainti...
- Associated Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH)
- Associated Therapies
- -
NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Stephen G. Kaler, MD
- Target Recruit Count
- 6
- Registration Number
- NCT04977388
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT03602014
- Locations
- 🇺🇸
James J. Peters Veteran's Affair Medical Center, Bronx, New York, United States
🇺🇸The Icahn School of Medicine at Mount Sinai, New York, New York, United States
Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2019-10-29
- Target Recruit Count
- 10
- Registration Number
- NCT03567447
- Locations
- 🇺🇸
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Loma Linda University
- Registration Number
- NCT03446807
- Locations
- 🇺🇸
Loma Linda University Faculty Medical Offices - Neurology Clinic, Loma Linda, California, United States
Brain Perfusion & Oxygenation in Parkinson's Disease With NOH
- Conditions
- Interventions
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- William Ondo, MD
- Target Recruit Count
- 17
- Registration Number
- NCT03229174
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Colorado Springs Neurological Associates
- Target Recruit Count
- 21
- Registration Number
- NCT03173781
- Locations
- 🇺🇸
Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States
Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT03115827
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT03070730
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Center for Autonomic and Peripheral Nerve Disorders - Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- The Cooper Health System
- Target Recruit Count
- 1
- Registration Number
- NCT03034564
- Locations
- 🇺🇸
Cooper University Health System, Camden, New Jersey, United States
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- Conditions
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT02897063
- Locations
- 🇺🇸
Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.